Cingulate to Participate in Benzinga All Live Access Event
August 15 2022 - 6:34PM
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical
company utilizing its proprietary Precision Timed Release™ (PTR™)
drug delivery platform technology to build and advance a pipeline
of next-generation pharmaceutical products, today announced that
Chairman and CEO Shane J. Schaffer will participate in a live
Benzinga All Access event on August 19, 2022, at 9 a.m. CST.
The discussion will address the current unmet needs in Attention
Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of
Cingulate’s PTR platform into the anxiety therapeutic area. Dr.
Schaffer will also provide a company overview.
The event may be viewed live on Benzinga’s YouTube
channel, Benzinga All Access, and will also
be available for viewing on Cingulate’s website
at cingulate.com/investors.
About
Cingulate® Cingulate Inc. (NASDAQ:
CING), is a clinical-stage biopharmaceutical company utilizing its
proprietary Precision Timed Release™ (PTR™) drug delivery platform
technology to build and advance a pipeline of next-generation
pharmaceutical products, designed to improve the lives of patients
suffering from frequently diagnosed conditions characterized by
burdensome daily dosing regimens and suboptimal treatment outcomes.
With an initial focus on the treatment of Attention
Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and
evaluating additional therapeutic areas where PTR technology may be
employed to develop future product candidates, including to treat
anxiety disorders.
Cingulate is headquartered in Kansas City. For more information
visit Cingulate.com
Investor Relations Thomas Dalton Head
of Investor & Public Relations,
CingulateTDalton@cingulate.com913-942-2301Matt KrepsDarrow
Associatesmkreps@darrowir.com214-597-8200Media
RelationsMelyssa WeibleElixir Health Public
Relationsmweible@elixirhealthpr.com201-723-5805
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jul 2023 to Jul 2024